How us antitrust can go astray: The brand name prescription drug litigation

International Journal of the Economics of Business

Volumn 4, Issue 3, 1997, Pages 239-256

  Scherer, F M ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

Antitrust policy; Health care; Jel classifications: k21, l41, l65, 111; Pharmaceuticals industry; Price discrimination; Retail pharmacies

Indexed keywords

EID: 84927093058     PISSN: 13571516     EISSN: 14661829     Source Type: Journal    
DOI: 10.1080/758523205     Document Type: Article

References (29)

1. Adelman, M.A., 1959. A&P: A Study in Price-Cost Behavior and Public Policy, Cambridge: Harvard University Press.
2. Avery, S.G., and Curtiss, F.R., 1995. “Can Chain Pharmacies Be MCOs? A Pilot Study,”. Drug Benefit Trends, May/June: 12–26.
3. Boston Consulting Group. April 1993. The Changing Environment for U. S. Pharmaceuticals, April, Boston: Boston Consulting Group. (Report commissioned by the Pharmaceutical Manufacturers Association)
4. Braeutigam, R.R., and Noll, R., 1984. “The Regulation of Surface Freight Transportation: The Welfare Effects Revisited,”. Review of Economics and Statistics, 66 February: 80–87.
5. Chandler, A.D., Jr. 1977. The Visible Hand: The Managerial Revolution in American Business, Cambridge: Harvard University Press.
6. Edwards, CD., 1959. The Price Discrimination Law, Washington: Brookings Institution.
7. Goldberg, L., and Greenberg, W., 1977. “The Health Maintenance Organization and Its Effects on Competition,”. Federal Trade Commission Bureau of Economics Staff Report. July1977, Washington.
8. Grabowski, H., and Vernon, J., 1966. “Longer Patents for Increased Generic Competition in the US,”. PharmacoEconomics, 19: 110–123. Supplement 2
9. Herman, E.S., 1959. “Fair Trade: Origins, Purposes, and Competitive Effects,”. George Washington University Law Review, 27: 588–621.
10. Hollander, S.C., 1966. “United States of America,”. In Resale Price Maintenance, Edited by: Yamey, B.S., 65–100. Chicago: Aldine.
11. Hutchcraft, C., 1996. ”Drugmakers’ Pact ‘Levels the Field’,”. Chicago Tribune, June: 1 22
12. Kruse, J., 1997. Wenbewerbspolitik im Spannungsfeld nationaler und inlemationaler Kartellrechtsordnungen, Baden–Baden: Nomas.
13. Malueg, D.A., 1993. “Bounding the Welfare Effects of Third-Degree Price Discrimination,”. American Economic Review, 83 September: 1011–1021.
14. Masson, A., and Steiner, R., 1985. “Generic Substitution and Prescription Drug Prices,”. Federal Trade Commission Bureau of Economics Staff Report. October1985, Washington.
15. Nahata, B., Ostaszewski, K., and Sahoo, P.K., 1990. “Direction of Price Changes in Third-Degree Price Discrimination,”. American Economic Review, 80 December: 1254–1258.
16. National Association of Retail Druggists. 1937. Fair Trade Manual Chicago
17. Newhouse, J.P., 1992. “Medical Care Costs: How Much Welfare Loss?”. Journal of Economic Perspectives, 6 Summer: 3–22.
18. Pharmaceutical Manufacturers Association. February 1994. “Advance Data: U.S. Pharmaceutical R&D and Sales,” February, Washington
19. Scherer, F.M., 1993. “Pricing, Profits, and Technological Progress in the Pharmaceutical Industry,”. Journal of Economic Perspectives, 7 Summer: 97–115.
20. Scherer, F.M., 1996. Industry Structure, Strategy, and Public Policy, New York: HarperCollins.
21. Scherer, F.M., and Ross, D., 1990. Industrial Market Structure and Economic Performance, 3rd edition, Boston: Houghton-Mifflin.
22. Scott, F.A., 1986. “Assessing USA Postal Ratemaking: An. Application of Ramsey Prices,”. Journal of Industrial Economics, 34 March: 279–290.
23. Shulman, S.R., 1996. “Healthcare Reform in the US,”. PharmacoEconomics, 10: 100–109. Supplement 2
24. US Bureau of the Census. August 1992. Money Income of Households, Families, and Persons in the United States: 1991, Current Population Report Series P-60 August, Washington
25. US Bureau of the Census. 1995. Statistical Abstract of the United States: 1995 Washington
26. US Congressional Budget Office. January 1996. How the Medicaid Rebate on Prescription Drugs Affects Pricing in the Pharmaceutical Industry, January, Washington: CBO Papers.
27. US Department of Health. December 1968. “ Education, and Welfare, Task Force on Prescription Drugs, Background Paper ”. In The Drug Makers and the Drug Distributors December, Washington
28. US Office of Technology Assessment. 1993. Pharmaceutical R&D: Costs, Risks and Rewards Washington
29. Varian, H., 1989. “Price Discrimination,”. In Handbook of Industrial Organization, Edited by: Schmalensee, R., and Willig, R.D., Vol.I, 597–654. Amsterdam: North–Holland.